CU20120159A7 - Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico - Google Patents
Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídicoInfo
- Publication number
- CU20120159A7 CU20120159A7 CU2012000159A CU20120159A CU20120159A7 CU 20120159 A7 CU20120159 A7 CU 20120159A7 CU 2012000159 A CU2012000159 A CU 2012000159A CU 20120159 A CU20120159 A CU 20120159A CU 20120159 A7 CU20120159 A7 CU 20120159A7
- Authority
- CU
- Cuba
- Prior art keywords
- peptide
- inhibitors
- proteasoma
- formulate
- procedure
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida.Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644122P | 2012-05-08 | 2012-05-08 | |
PCT/US2012/055127 WO2013169282A1 (en) | 2012-05-08 | 2012-09-13 | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20120159A7 true CU20120159A7 (es) | 2014-03-26 |
Family
ID=49549072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2012000159A CU20120159A7 (es) | 2012-05-08 | 2012-11-12 | Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico |
Country Status (21)
Country | Link |
---|---|
US (2) | US20130303465A1 (es) |
JP (1) | JP2015516416A (es) |
KR (1) | KR20150007361A (es) |
CN (1) | CN103781490A (es) |
AR (2) | AR087863A1 (es) |
AU (1) | AU2012238318B2 (es) |
BR (1) | BR112012028726B1 (es) |
CA (1) | CA2793894A1 (es) |
CO (1) | CO6571868A2 (es) |
CR (1) | CR20120485A (es) |
CU (1) | CU20120159A7 (es) |
DO (1) | DOP2012000252A (es) |
EA (1) | EA201201519A1 (es) |
EC (1) | ECSP12012167A (es) |
MA (1) | MA35238B1 (es) |
MX (1) | MX2012010891A (es) |
MY (2) | MY196510A (es) |
SG (1) | SG194417A1 (es) |
TW (1) | TWI603737B (es) |
WO (1) | WO2013169282A1 (es) |
ZA (1) | ZA201207384B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
DK2970225T3 (en) | 2013-03-14 | 2018-09-24 | Onyx Therapeutics Inc | DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS |
GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
WO2015009888A2 (en) | 2013-07-19 | 2015-01-22 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
CN103936828A (zh) * | 2014-05-12 | 2014-07-23 | 苏州科耐尔医药科技有限公司 | 卡非佐米中间体及卡非佐米的制备方法 |
CN105919972A (zh) * | 2015-12-18 | 2016-09-07 | 重庆两江药物研发中心有限公司 | 一种包载卡非佐米的纳米粒制剂及其制备方法 |
TWI759301B (zh) * | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
UA125648C2 (uk) | 2016-08-05 | 2022-05-11 | Емджен Інк. | Синтез (s)-2-аміно-4-метил-1-((r)-2-метилоксиран-2-іл)-пентан-1-ону та його фармацевтично прийнятних солей |
WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
US20180282260A1 (en) * | 2017-03-31 | 2018-10-04 | Valent Biosciences Llc | 1-aminocyclopropane-1-carboxylic acid polymorphs |
US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
CN111344018A (zh) | 2017-11-16 | 2020-06-26 | 美国安进公司 | 聚乙二醇化卡非佐米化合物的稳定的组合物 |
EP3716948B1 (en) * | 2017-11-30 | 2023-11-22 | Cytogel Pharma, LLC | Novel analgesic pharmaceutical formulations and uses thereof |
AU2021292417A1 (en) * | 2020-06-19 | 2023-01-19 | Amgen Inc. | Methods of measuring carfilzomib |
US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE499109T1 (de) * | 2004-12-07 | 2011-03-15 | Proteolix Inc | Zusammensetzung zur proteasomhemmung |
KR101274417B1 (ko) * | 2005-11-09 | 2013-06-17 | 프로테올릭스, 인코퍼레이티드 | 효소 저해를 위한 화합물 |
MY173938A (en) * | 2007-10-04 | 2020-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
-
2012
- 2012-09-13 BR BR112012028726-5A patent/BR112012028726B1/pt active IP Right Grant
- 2012-09-13 TW TW101133449A patent/TWI603737B/zh active
- 2012-09-13 JP JP2015511431A patent/JP2015516416A/ja active Pending
- 2012-09-13 EA EA201201519A patent/EA201201519A1/ru unknown
- 2012-09-13 MX MX2012010891A patent/MX2012010891A/es not_active Application Discontinuation
- 2012-09-13 MY MYPI2017001061A patent/MY196510A/en unknown
- 2012-09-13 AR ARP120103377A patent/AR087863A1/es not_active Application Discontinuation
- 2012-09-13 WO PCT/US2012/055127 patent/WO2013169282A1/en active Application Filing
- 2012-09-13 KR KR1020127028681A patent/KR20150007361A/ko not_active Application Discontinuation
- 2012-09-13 MY MYPI2012005407A patent/MY165002A/en unknown
- 2012-09-13 CA CA2793894A patent/CA2793894A1/en not_active Abandoned
- 2012-09-13 SG SG2012084075A patent/SG194417A1/en unknown
- 2012-09-13 US US13/614,599 patent/US20130303465A1/en not_active Abandoned
- 2012-09-13 AU AU2012238318A patent/AU2012238318B2/en active Active
- 2012-09-13 CN CN201280001354.7A patent/CN103781490A/zh active Pending
- 2012-09-13 US US13/614,829 patent/US20130303482A1/en not_active Abandoned
- 2012-09-26 CR CR20120485A patent/CR20120485A/es unknown
- 2012-09-26 EC ECSP12012167 patent/ECSP12012167A/es unknown
- 2012-09-27 DO DO2012000252A patent/DOP2012000252A/es unknown
- 2012-09-28 CO CO12170407A patent/CO6571868A2/es not_active Application Discontinuation
- 2012-10-02 ZA ZA2012/07384A patent/ZA201207384B/en unknown
- 2012-11-12 CU CU2012000159A patent/CU20120159A7/es unknown
-
2013
- 2013-12-04 MA MA36520A patent/MA35238B1/fr unknown
-
2022
- 2022-12-02 AR ARP220103323A patent/AR127861A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG194417A1 (en) | 2013-12-30 |
MA35238B1 (fr) | 2014-07-03 |
EA201201519A1 (ru) | 2013-11-29 |
AR087863A1 (es) | 2014-04-23 |
AU2012238318A1 (en) | 2013-11-28 |
AR127861A2 (es) | 2024-03-06 |
TW201345543A (zh) | 2013-11-16 |
ECSP12012167A (es) | 2013-02-28 |
CO6571868A2 (es) | 2012-11-30 |
CN103781490A (zh) | 2014-05-07 |
US20130303465A1 (en) | 2013-11-14 |
MY196510A (en) | 2023-04-18 |
BR112012028726A2 (pt) | 2016-07-19 |
MY165002A (en) | 2018-02-28 |
BR112012028726B1 (pt) | 2021-07-13 |
ZA201207384B (en) | 2018-12-19 |
WO2013169282A1 (en) | 2013-11-14 |
US20130303482A1 (en) | 2013-11-14 |
CR20120485A (es) | 2013-12-18 |
NZ602490A (en) | 2016-03-31 |
KR20150007361A (ko) | 2015-01-21 |
MX2012010891A (es) | 2014-03-05 |
DOP2012000252A (es) | 2013-12-31 |
JP2015516416A (ja) | 2015-06-11 |
AU2012238318B2 (en) | 2014-02-13 |
TWI603737B (zh) | 2017-11-01 |
CA2793894A1 (en) | 2013-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20120159A7 (es) | Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico | |
CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
CL2017000969A1 (es) | Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014) | |
ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
GT201400178A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
BR112016012146A8 (pt) | derivados de aminopiridina como inibidores de quinase da família tam | |
CR20150250A (es) | Nuevos derivados de piridina | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
CO7151512A2 (es) | Inhibidores del nampt | |
BR112016013419A2 (pt) | composições de liberação retardada de linaclotida | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
TR201909447T4 (tr) | Aramkol tuzları. | |
CO7350640A2 (es) | Compuestos diméricos | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
UY34078A (es) | Composiciones farmacéuticas y métodos para tratar el cáncer | |
DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
UY34829A (es) | Nueva dosificación y formulación | |
MX358132B (es) | Solucion de trombina y metodos de uso de esta. | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
BR112014019220A8 (pt) | Novos derivados de pirrolidina | |
GEP201706675B (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
UY35004A (es) | Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
BR112013027391A2 (pt) | formulação farmacêutica, frasco e kit |